Mainstay Medical
Mainstay Medical is a medical device company that developed ReActiv8, an FDA-approved restorative neurostimulation system for chronic low back pain.
Secondary Market Price
How Mainstay Medical Measures Up
To help you manage your Mainstay Medical equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
TBD
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Mainstay Medical's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Mainstay Medical Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Mainstay Medical's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Mainstay Medical is a medical device company engaged in the development and commercialization of ReActiv8, an implantable neurostimulation system designed to treat mechanical chronic low back pain (CLBP). The therapy targets the multifidus muscle to restore control and spinal stability. It is the first FDA-approved restorative treatment for this condition. Founded in 2008 in Dublin, Ireland, the company has since established its primary headquarters in San Diego, California, with subsidiaries in Australia, Germany, and the Netherlands. Mainstay Medical is listed on the Euronext Paris and the Irish Stock Exchange.
The company is focused on accelerating global access to its ReActiv8 therapy. Recent milestones include the publication of the RESTORE randomized controlled trial and securing its first national commercial coverage policy in the U.S. with Anthem BCBS. Mainstay Medical continues to present new clinical findings at scientific gatherings, such as the two-year outcomes from the RESTORE study at a North American Neuromodulation Society (NANS) meeting. To support its expansion efforts, the company completed a private equity funding round in March 2024, raising $125 million.
- Gilde Healthcare
- Viking Global Investors
- Ally Bridge Group
- Sofinnova Partners
- Fountain Healthcare Partners
- Perceptive Advisors
- Co-Founder, Dan Sachs
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Mainstay Medical worth joining?
Deciding whether to join Mainstay Medical depends on your personal career goals and an assessment of the company's future prospects and the value of its equity compensation. Tools like Prospect can help you analyze the potential value of your equity offer by using predictive models trained on data used by top VCs.
What should I do with my Mainstay Medical stock?
Managing your Mainstay Medical stock involves creating a strategy that aligns with your financial goals, tax situation, and risk tolerance. You can use Prospect to build a customized plan for exercising options or selling shares at the most opportune times to maximize your earnings.
Can you sell Mainstay Medical stock?
Selling stock in a private company like Mainstay Medical is typically possible only during specific events, such as company-approved tender offers or on secondary markets. Prospect offers tools to help you navigate these opportunities and determine the tax-optimal shares to sell.
How can I find the value of my Mainstay Medical stock?
Valuing stock in a private company like Mainstay Medical is challenging because it doesn't trade on a public exchange. Platforms like Prospect use machine learning models and data from funding rounds and secondary markets to project your equity's future value.
What is Mainstay Medical's equity worth?
The precise worth of Mainstay Medical's equity is not publicly known and depends on factors like its latest 409A valuation and future growth potential. To get a data-driven estimate, you can use Prospect’s predictive models, which forecast a range of likely outcomes for your private company shares.
What is Mainstay Medical's stock ticker symbol?
As a private company, Mainstay Medical does not have a stock ticker symbol because its shares are not traded on a public stock exchange. Ticker symbols are assigned to companies only when they become publicly listed through an Initial Public Offering (IPO).
Can I buy or sell Mainstay Medical stock?
Buying shares in a private company like Mainstay Medical is generally restricted to accredited investors during funding rounds, while selling is limited to events like tender offers. If you are an employee looking to sell, Prospect provides tools to help you make informed decisions during these liquidity events.
What is the criteria to buy or invest in Mainstay Medical stock?
Investing in a private company like Mainstay Medical is typically reserved for accredited investors who meet specific income or net worth requirements set by financial regulators. Employees may also receive equity as part of their compensation, which provides another path to holding stock in the company.
